نتایج جستجو برای: tyr octreotide

تعداد نتایج: 8948  

Journal: :Gut 1995
N Davies H Kynaston J Yates B A Taylor S A Jenkins

The inhibitory effect of octreotide on the growth of liver tumour is probably mediated (at least in part) by stimulation of the hepatic reticuloendothelial system (RES) activity. This study therefore investigated the effect of octreotide on the hepatic and splenic RES (assessed by the uptake of technetium 99m labelled albumin colloid, 99mTc-AC) in normal and tumour bearing rats and in animals t...

2001
X Su M B Burton G F Gebhart

Background and aims—It has been suggested that the analgesic eVect of the somatostatin analogue octreotide in visceral pain involves peripheral mechanisms. We evaluated the eVect of octreotide on responses to noxious colorectal distension in rats. Methods—In a behavioural study, pressor and electromyographic responses to colorectal distension were evaluated before and after intravenous or intra...

Journal: :Pancreas 2010
Saju Joseph Gang Li Erika Lindholm Ying Zhou Vay Liang W Go Aaron I Vinik Thomas M O'Dorisio Gregg Mamikunian Eugene A Woltering

OBJECTIVES Octreotide long acting repeatable (LAR) is commonly used to control the symptoms of patients with functional neuroendocrine tumors. Unfortunately, most patients escape control over time and require higher LAR doses or more frequent rescue therapy to remain asymptomatic. Previous work has shown that body weight and monthly LAR dose will significantly affect circulating plasma octreoti...

Journal: :Hormone research in paediatrics 2015
Sinian Pan Min Zhang Yinya Li

AIMS Hyperinsulinemic hypoglycemia (HH) is common in small-for-gestational-age (SGA) neonates. Diazoxide is often used as the first-line medication for HH in SGA neonates. Unfortunately, diazoxide is not authorized in China. We examined the effectiveness of octreotide as an alternative therapy to treat HH in SGA neonates. There is limited data on the use of octreotide in HH of SGA neonates. M...

Journal: :Gut 1996
R Arnold M E Trautmann W Creutzfeldt R Benning M Benning C Neuhaus R Jürgensen K Stein H Schäfer C Bruns H J Dennler

Antiproliferative treatment of patients with metastatic endocrine gastroenteropancreatic tumours (GEP) is based mainly on chemotherapeutic protocols whereby drug toxicity is a major handicap. Octreotide is the first choice in the control of hormone mediated symptoms. From retrospective and a few prospective studies it has been suggested that octreotide exhibits antiproliferative properties. The...

Journal: :The oncologist 2013
Daniel Castellano Emilio Bajetta Ashok Panneerselvam Stephen Saletan Walter Kocha Thomas O'Dorisio Lowell B Anthony Timothy Hobday

INTRODUCTION The incidence of colorectal neuroendocrine tumors (NETs) is increasing, and patients with this disease have particularly poor prognoses. Treatment options are limited, and survival times have not improved in the past decade. METHODS A post hoc analysis of the efficacy and tolerability of everolimus plus octreotide long-acting repeatable (LAR) was conducted in patients with colore...

Journal: :Cancer research 1999
S Froidevaux E Hintermann M Török H R Mäcke C Beglinger A N Eberle

Octreotide is a somatostatin analogue that is widely used for cancer therapy and tumor imaging. Its efficacy in tumors depends mainly on the expression of the somatostatin receptor type 2 (sst 2). Desensitization and down-regulation of sst 2 after agonist exposure can have important consequences for patients under ongoing octreotide therapy because it may induce temporary tumor unresponsiveness...

Journal: :Gut 1992
K F Binmoeller A G Harris R Dumas C Grimaldi J P Delmont

This study evaluates the effect of the long acting somatostatin analogue octreotide on biochemical and clinical parameters of endoscopic retrograde cholangiopancreatography (ERCP) induced pancreatitis. Altogether 245 patients were randomised to receive either octreotide or isotonic saline. Octreotide (100 micrograms) was administered intravenously five minutes before ERCP and subcutaneously 45 ...

2015
Edward M Wolin Barbara Jarzab Barbro Eriksson Thomas Walter Christos Toumpanakis Michael A Morse Paola Tomassetti Matthias M Weber David R Fogelman John Ramage Donald Poon Brian Gadbaw Jiang Li Janice L Pasieka Abakar Mahamat Fredrik Swahn John Newell-Price Wasat Mansoor Kjell Öberg

In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) eve...

Journal: :Hepatology 2007
Gerhild Becker Hans-Peter Allgaier Manfred Olschewski Andreas Zähringer Hubert Erich Blum

UNLABELLED Although numerous treatment modalities have been explored in patients with advanced HCC, the therapeutic options are still limited. Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors. Expression of somatostatin receptors is found in HCCs, but the efficacy of the somatostatin analogue octreotide remains controversial. T...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید